What is fetal hemglobin?

Fetal hemoglobin (HbF) is the principal hemoglobin component in human fetuses and newborns, accounting for 50%–90% of normal hemoglobin.

- It begins synthesis at approximately six weeks of gestation and continues to be the dominant form of hemoglobin until birth, when it is gradually replaced by adult hemoglobin (HbA).

Structure:

- HbF is a tetramer composed of two alpha-globin chains (α2) and two gamma-globin chains (γ2).

- This differs from adult hemoglobin (HbA), which consists of two alpha-globin chains and two beta-globin chains (α2β2).

Function:

- HbF has a higher affinity for oxygen compared to HbA, allowing it to efficiently transport oxygen from the placenta to the fetus in the womb.

- The increased oxygen affinity of HbF is attributed to the presence of gamma-globin chains, which have a higher affinity for oxygen than beta-globin chains.

Clinical Significance:

- In certain individuals, elevated levels of HbF may persist after birth, a condition known as hereditary persistence of fetal hemoglobin (HPFH).

- HPFH is usually benign, but it can sometimes be associated with an increased susceptibility to certain blood disorders.

Medical Uses:

- HbF has therapeutic applications in certain medical conditions, including sickle cell anemia and beta-thalassemia.

- In these disorders, abnormally structured hemoglobin (HbS in sickle cell anemia and reduced β-globin production in beta-thalassemia) causes red blood cell abnormalities and can lead to complications such as anemia, pain crises, and organ damage.

- Providing the body with HbF can help alleviate some of these complications and improve overall health in individuals with these disorders.